{"id":"buccal-midazolam","safety":{"commonSideEffects":[{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL655","moleculeType":"Small molecule","molecularWeight":"325.77"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Midazolam binds to benzodiazepine receptors on GABA-A channels, increasing chloride influx and hyperpolarizing neurons, which reduces neuronal excitability. The buccal formulation allows rapid absorption through the oral mucosa, providing faster onset than oral administration. This is particularly useful for acute seizure management and pre-procedural sedation in settings where intravenous access is unavailable or undesirable.","oneSentence":"Buccal midazolam is a benzodiazepine that enhances inhibitory GABAergic neurotransmission in the central nervous system to produce sedation and anxiolysis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:29.201Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute seizure management, particularly in pediatric patients"},{"name":"Pre-procedural sedation and anxiolysis"},{"name":"Acute agitation and anxiety"}]},"trialDetails":[{"nctId":"NCT05313308","phase":"","title":"A Survey of Midazolam in People With Status Epilepticus","status":"RECRUITING","sponsor":"Clinigen K.K.","startDate":"2021-06-01","conditions":"Epilepsy","enrollment":50},{"nctId":"NCT06752616","phase":"PHASE2, PHASE3","title":"Acute Agitation in Emergency Psychiatry","status":"RECRUITING","sponsor":"Lone Baandrup","startDate":"2024-12-30","conditions":"Agitation","enrollment":132},{"nctId":"NCT06194747","phase":"NA","title":"Improving Status Epilepticus Treatment Times","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2024-02-01","conditions":"Status Epilepticus","enrollment":450},{"nctId":"NCT06056349","phase":"NA","title":"Benzodiazepine Study for the Treatment of Seizure Clusters in a Third Level Mexican Neurological Center","status":"RECRUITING","sponsor":"El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez","startDate":"2023-05-01","conditions":"Cluster Seizure","enrollment":150},{"nctId":"NCT06389318","phase":"NA","title":"Buccal Midazolam Versus Intranasal Dexmedetomidine Plus Oral Chloral Hydrate in Inguinal Hernia Repair","status":"COMPLETED","sponsor":"Benha University","startDate":"2023-03-26","conditions":"Inguinal Hernia Repair","enrollment":80},{"nctId":"NCT05670509","phase":"PHASE4","title":"Intranasal vs Buccal vs Intramuscular Midazolam for the Home and Emergency Treatment of Acute Seizures","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-01-19","conditions":"Convulsions","enrollment":305},{"nctId":"NCT03336450","phase":"PHASE3","title":"Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting","status":"COMPLETED","sponsor":"Shire","startDate":"2018-04-23","conditions":"Nervous System Diseases","enrollment":3},{"nctId":"NCT04608734","phase":"PHASE2","title":"Buccal Versus Intranasal Route of Administration of Midazolam Spray in Behavior Management of Pre-School Patients","status":"COMPLETED","sponsor":"Nourhan M.Aly","startDate":"2015-06-10","conditions":"Dental Anxiety","enrollment":36},{"nctId":"NCT03336645","phase":"PHASE3","title":"Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan","status":"COMPLETED","sponsor":"Shire","startDate":"2017-10-23","conditions":"Nervous System Diseases","enrollment":25},{"nctId":"NCT02897856","phase":"PHASE4","title":"Efficacy and Safety of Intramuscular Midazolam Compared to Buccal Midazolam in Pediatric Seizures","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2016-09","conditions":"Seizures","enrollment":150},{"nctId":"NCT00675909","phase":"NA","title":"Improving Sedation of Children Undergoing Procedures in the Emergency Department","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2006-11","conditions":"Anxiety","enrollment":180},{"nctId":"NCT02009306","phase":"PHASE4","title":"Nasal Fentanyl and Buccal Midazolam for Dying Patients","status":"COMPLETED","sponsor":"Gloucestershire Hospitals NHS Foundation Trust","startDate":"2017-01-23","conditions":"Terminal Cancer","enrollment":20},{"nctId":"NCT02408302","phase":"PHASE4","title":"Buccal Midazolam Versus Nasal or Oral Midazolam Sedation for Minor Invasive Procedures in Children","status":"UNKNOWN","sponsor":"Carmel Medical Center","startDate":"2015-04","conditions":"Dormicum, Conscious Sedation, Children","enrollment":90},{"nctId":"NCT01316445","phase":"PHASE1","title":"Pharmacodynamics of Nasal and Buccal Midazolam Using EEG","status":"TERMINATED","sponsor":"Columbia University","startDate":"2011-07","conditions":"Epilepsy","enrollment":9}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACCIDENT"},{"count":1,"reaction":"AUTOSOMAL CHROMOSOME ANOMALY"},{"count":1,"reaction":"BALANCE DISORDER"},{"count":1,"reaction":"DISTURBANCE IN ATTENTION"},{"count":1,"reaction":"DRUG INTERACTION"},{"count":1,"reaction":"FATIGUE"},{"count":1,"reaction":"FEELING ABNORMAL"},{"count":1,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"},{"count":1,"reaction":"HEADACHE"},{"count":1,"reaction":"HOSPITALISATION"}],"_approvalHistory":[],"publicationCount":122,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Buccal midazolam","genericName":"Buccal midazolam","companyName":"Hamad Medical Corporation","companyId":"hamad-medical-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buccal midazolam is a benzodiazepine that enhances inhibitory GABAergic neurotransmission in the central nervous system to produce sedation and anxiolysis. Used for Acute seizure management, particularly in pediatric patients, Pre-procedural sedation and anxiolysis, Acute agitation and anxiety.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}